Zacks Investment Research upgraded shares of MDxHealth (OTCMKTS:MXDHF) from a sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “
Shares of OTCMKTS MXDHF opened at $2.35 on Wednesday. The stock has a market cap of $140.86 million, a PE ratio of -9.40 and a beta of 1.13. MDxHealth has a 52-week low of $1.75 and a 52-week high of $5.00.
MDxHealth Company Profile
MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
Further Reading: How accurate is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.